A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
收藏DataCite Commons2026-03-11 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004855/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate when co-administered with prednisone in Asian patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed docetaxel-based chemotherapy.
提供机构：
Vivli
创建时间：
2019-09-19
